Aktienanalyse zu Syndax Pharmaceuticals Inc (SNDX)SNDXSyndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Syndax Pharmaceuticals is currently not a strong buy due to its recent disappointing trial results and high volatility. The stock is priced at $13.4, with an RSI of 30.214 indicating it is oversold. However, the forward P/E ratio is 0, suggesting uncertainty in earnings expectations. The main risk is the significant net loss of $49.36 million reported in Q2 2026, which may deter investors. Given these factors, it is advisable to hold rather than buy at this time.

8 analysts cover SNDX: 8 rate it Buy, 0 Hold and 0 Sell. The average price target is 39.11.